The Council of Scientific and Industrial Research (CSIR) has sanctioned the project to develop human monoclonal antibodies which will work as a therapy for COVID-19 infections. The council has passed the project under its flagship named the New Millennium Indian Technology Leadership Initiative Programme (NMITLI).

The Council of Scientific and Industrial Research (CSIR), through its New Millennium Indian Technology Leadership Initiative (NMITLI) program, has approved a multi-institutional project to develop human monoclonal antibodies (hmAbs) that can neutralize coronavirus in patients.

CSIR is leading the fight against Covid-19 using multi-pronged approach and multiple models of engagement. On one hand CSIR labs themselves are developing technologies and products and are working with industry and PSU partners for deployment. On the other hand, CSIR is also supporting new ideas